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A B S T R A C T
The potential use of cholesterol esterases was tested to avoid alkaline hydrolysis for cleavage of plasma ester-
ified oxysterols. The enzymatic hydrolysis was optimized by testing two sources of enzyme—Pseudomonas
and bovine pancreas, presence of surfactants, incubation time and amount of enzyme. Free forms of 4β-, 7-,
24-, 25- and 27-hydroxycholesterol (HC) as well 7-ketocholesterol (7-KC) were analyzed by liquid chro-
matography and mass-spectrometry using the deuterated internal standard, 25-HC(d6). Enzymatic hydrolysis
was more effective using the Pseudomonas enzyme and in presence of surfactants. Compared to alkaline hy-
drolysis, it generated a cleaner chromatographic baseline and better recovery of the internal standard. Oxys-
terols were assayed with detection limits between 7 and 31 pg/mL. Interassay coefficients of variation were
lower than 10% and extraction recovery efficiencies, higher than 90%. The procedure was used to character-
ize plasma levels of Cyp7b1-deficient rat, where it showed increased plasma levels of 7, 24 and 25-HC. Due
to the low volume of sample required, it may be used in other animal models, particularly rodents, as well as
in pediatric samples where sample amount is always a problem. Thus, the proposed new method offers mild




Oxysterols, particularly those presenting the hydroxyl radical at
positions 25 and 27 (Fig. 1), are enzymatically derived oxidation
products of cholesterol that are lately being associated with highly
prevalent diseases [1]. In this regard, as oxysterols are metabolites
of cholesterol, they have mainly been studied in cardiovascular dis-
eases [2]. When they accumulate, they have toxic effects on several
cell types. For instance, 25-hydroxycholesterol (25-HC) and 7-keto-
cholesterol (7-KC) were shown to induce apoptosis of smooth mus-
cle cells via the mitochondrial pathway and reactive oxygen species
generation [3]. In macrophages, incubation with 25-HC reportedly ac
Abbreviation: 4-βHC, 4β-hydroxycholesterol; 7-HC, 7-hydroxycholesterol;
7-KC, 7-ketocholesterol; 24-HC, 24-hydroxycholesterol; 25-HC, 25-hydroxycho-
lesterol; 27-HC, 27-hydroxycholesterol; LC–MS, liquid chromatography-mass
spectrometry; SIR, single ion recording; SPE, solid phase extraction
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tivates stress response genes and reprograms protein translation, in-
dependently of liver X receptors and sterol-response element-binding
proteins [4]. It has also been shown that the production of 25-HC pro-
motes the transformation of macrophages into foam cells in athero-
sclerotic plaques [5]. Moreover, 25-HC has been proposed to exert
antiviral activity [6]. Likewise, oxysterols have been a matter of in-
tense research in the nervous system, where their accumulation has
been found to modify oxidative stress [7], apoptosis [8] and cell death
in several types of neural cells such as PC12 cells [9,10] and sympa-
thetic [11], retinal [12] and cerebellar [13] neurons. 25-HC has also
been proposed as a marker of Alzheimer's disease progression due
to its ability to modulate choline acetyltransferase [14] and an eti-
ological agent in amyotrophic lateral sclerosis [15]. Finally, 25-HC
has been found to regulate the activity of estrogen receptors alpha
and beta [16], which could cause reproductive disorders. Likewise, it
has been reported to be involved in breast and ovarian cancer [2], as
well as other types of cancer, and even in metastasis, through oxys-
terol binding protein [17,18]. Plasma 24-HC and 27-HC seem to be
sensitive biomarkers for the evaluation of mild cognitive impairment
and Alzheimer's disease [19]. Brain 7-KC, 7-HC and 4beta-HC lev-
els have also been found associated with progression of this disease
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Fig. 1. Chemical structure of cholesterol and its oxysterol derivatives.
tential biomarkers of multiple sclerosis [21]. Plasma 4beta-HC has
been proposed as a subrogate marker to assess hepatic CYP3A induc-
tion [22,23].
Plasma levels of 25- and 27-hydroxycholesterol were similarly el-
evated in mice lacking oxysterol 7alpha-hydroxylase CYP7B1 [24].
Thus, it was proposed that this enzyme could have a major role in
their metabolism. In contrast, patients displaying low CYP7B1 activ-
ity showed dramatic increases in plasma 25-HC levels and only mod-
erate in those of 27-HC [25]. These data indicate a preferential se-
lectivity of the enzyme according to species. To further support this
hypothesis, plasma oxysterol profile needs to be characterized in rats
with inactivated Cyp7b1 gene.
Due to the above-mentioned findings, much interest has been de-
voted to improve the quantitation of oxysterols, which is compli-
cated by their low plasma concentrations (in the range of ngmL−1).
In fact, cholesterol is approximately 1000 times more abundant than
the next most abundant oxysterol [26]. Special efforts have been made
to isolate the analytes from the plasma lipoproteins, their natural con-
veyance through the bloodstream. To this purpose, several extraction
methods have been employed to remove interfering proteins [27,28].
Recently, the use of dichloromethane/methanol has been proposed
to protect the sample and workers exposed to organic solvents [26].
Furthermore, their total quantification requires an alkaline hydroly-
sis step to transform oxysterol esters to free forms [29–33]. However,
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duces sample integrity due to the degradation of triglycerides and
phospholipids [26]; it also generates unspecific and undesirable prod-
ucts from 7-ketocholesterol in a time-dependent manner, which may
interfere during the chromatographic analysis as a source of high
backgrounds [34]. The release of fatty acids and generation of 7-ke-
tocholesterol degradation products complicate the analysis [26] so to
avoid these byproducts, a final step of purification by solid phase ex-
traction (SPE) is usually undertaken. Sometimes, to increase the sig-
nal level of these metabolites, derivatizations are performed [35,36],
which add another step to sample processing. The present manuscript
successfully explores the use of cholesterol esterases to free esteri-
fied oxysterols and avoid the described complications when alkaline
hydrolysis is used. In addition, the proposed new method greatly im-
proves sample handling.
2. Material and methods
2.1. Reagents
Standards used were 4β-HC (99% purity, CAS 17320-10-4),
7α-HC (99% purity, CAS 566-26-7), 7β-HC (99% purity, CAS
566-27-8), 7-keto cholesterol (99% purity, CAS 566-28-9), 24(S)-HC
(99% purity, CAS 474-73-7), 25-HC (99% purity, CAS 2140-46-7),
27-HC (99%, CAS 20380-11-1), 25-HC(d6) (internal standard 99%,
CAS 88247-69-2) and 27-HC(d6) (internal standard 99%, CAS
1246302-95-3), purchased from Avanti Polar Lipids (Alabaster, AL,
USA). Cholesteryl stearate (96%, CAS 35602-69-8), potassium hy-
droxide (85%, CAS 1310-58-3), butylated hydroxytoluene (BHT)
(99%, CAS 128-37-0) and Triton X-100 (99%, CAS 9002-93-1) were
purchased from Sigma-Aldrich (Madrid, Spain). Except cholesteryl
stearate, which was dissolved in hexane, all standard solutions were
prepared in methanol at a concentration of 1mg mL−1 and stored at
−20°C. Cholesterol esterases from Pseudomonas sp. (CAS
9026-00-0) and from bovine pancreas (CAS 9026-00-0) were pur-
chased from Invitrogen (Barcelona, Spain) and prepared at a concen-
tration of 200U/mL in 0.1M potassium phosphate (KH2PO4), 0.05M
sodium chloride, 5mM cholic acid and 0.1% Triton X-100. Solvents
used, such as methanol (analytical grade LC–MS, CAS 67-56-1),
ethanol (analytical HPLC grade CAS 67-63-0), chloroform (analyt-
ical HPLC grade CAS 67-66-3) and hexane (96%; CAS 110-54-3),
were provided by Sharlab (Barcelona, Spain). Water was supplied by
a Milli-Q Plus 186 (Millipore, Billerica, MS, USA) system.
2.2. Sample handling
Cyp7b1-deficient (knock-out or KO) rats were purchased from
Transposagen BioPharmaceuticals (Lexington, KY, U.S.A). These
rats were generated by transposon-mediated gene-trap insertional mu-
tagenesis in the Fischer F344 strain [37] at the Medical College of
Wisconsin under protocols approved by the Institutional Animal Care
and Use Committee (IACUC). A single male offspring was iden-
tified harboring a gene-trap transposon insertion in the first intron
of Cyp7b1 that was predicted to truncate normal transcription. This
male was backcrossed to the Fisher 344 strain and heterozygous car-
riers were intercrossed to generate homozygous animals for experi-
ments. A three-primer assay using primers B3-306_F: 5′-AAACAT-
CACCTTCTGCAGAGGAC-3′, B3-306_R: 5′-CCCTATTTG-
TATCTTGCTCAGCTTT-3′, and ITR-L: 5′-CCTAACTGACTTGC-
CAAAAC-3′ were used to confirm the gene-trap insertion and geno-
type the animals for zygosity. No message was observed by RT-PCR
in any of the tissues studied (data not shown).
Blood from male wild-type (WT) Fisher 344 and homozygous
Cyp7b1-deficient rats on chow diet was obtained by intracardiac punc-
ture from left ventricle in CO2-euthanized animals. Identical proce-
dure was used to obtain blood from Apoe-deficient mice on chow
diet as well. A volunteer subject consented to give his blood for the
experiment once used for a medical revision. The protocol was ap-
proved by the Ethics Committee for Animal Research of the Uni-
versity of Zaragoza. Blood (1 mL) was immediately mixed with 6μL
of 0.5M EDTA dissolved in phosphate-buffered saline (PBS). Blood
tubes were kept on ice and centrifuged at 1150g for 10min to separate
plasma. The latter was aliquoted, deep-frozen in liquid nitrogen and
stored at −80°C until further processing. Samples, thawed on crushed
ice, were processed without breaking the cold chain.
2.3. Determination of oxysterols
2.3.1. Free oxysterols
Three extraction methods were tested: those of Folch et al. [28] and
Bligh and Dyer [27], and that described by McDonald et al. [26], be-
ing the Folch the most effective in terms of extraction recovery and
quality. Briefly, 100μL of rat plasma were placed in capped 10mL
glass tubes, to which 0.75mL of chloroform/methanol (2:1, v/v) mix-
ture containing 4.5μL of 9.5μgmL−1 25-HC(d6) as internal standard
and 6.5μL of 1150μgmL−1 BHT, both in methanol, were added.
Then, 0.25mL of chloroform were added and homogenized. Finally,
0.25mL of Milli-Q water were mixed by shaking for 10min. The mix-
ture was centrifuged at 622g for 10min and the lower organic phase
was recovered. Two further cycles of extraction, homogenization and
centrifugation were carried out. Combined organic phases were evap-
orated to dryness under N2 stream at 40°C. Solid extracts were dis-
solved in 1mL of hexane with the aid of sonication for 5min.
2.3.2. Total oxysterols: alkaline hydrolysis
To cleave oxysterol-fatty acid conjugates, two different alkaline
hydrolysis procedures were applied to the combined organic phases,
that described by DeBarber et al. [32] and the more sterol-specific al-
kaline hydrolysis method proposed by McDonald et al. [26]. A sum-
mary of steps in all procedures is shown in Fig. 2.
2.3.3. Total oxysterols: enzymatic hydrolysis
After optimization, the best experimental conditions were set up
as follows: 100μL of plasma were carefully mixed with 100μL of
potassium phosphate (pH 7.4, 0.5M) containing 0.25M NaCl, 25mM
cholic acid and 0.5% Triton® X-100 and 1.6 units of Pseudomonas
cholesterol esterase in a 0.2mL tube. Samples were incubated at 37°C
for 60min in a Biorad thermal cycler (Hercules, CA, USA). After the
enzymatic hydrolysis, samples underwent free oxysterol quantifica-
tion.
2.4. Solid phase extraction
Samples were purified by solid phase extraction (SPE)
MFE®-PAK Amino cartridges (500mg/3mL) (Análisis Vínicos, S.L,
Tomelloso, Ciudad Real, Spain) using a manifold system from Wa-
ters (Milford, MA, USA). Vacuum was adjusted to maintain a flow
of 1.0–1.5mL/min. Solvents and conditions are described in supple-
mental Table 1. Eluted samples were evaporated to dryness under N2
stream at 40°C and then dissolved in 0.12mL of methanol/Milli-Q
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Fig. 2. Overview of compared analytical methods.
2.5. LC/MS analysis
An ultra-high resolution ACQUITY UPLC™ H-Class liquid chro-
matograph from Waters (Milford, MA, USA) equipped with an AC-
QUITY UPLC™ BEH C18 2.1mm × 150mm column and 1.7 μm par-
ticle diameter was used. Mobile phases were 0.1% formic acid in
methanol (v/v) (A) and 0.1% formic acid in Milli-Q water (v/v) (B).
The flow was set at 0.3mL/min. Injection volume was 20μL. Tem-
peratures of column and samples were 40 and 10°C, respectively. The
chromatograph was coupled to an ACQUITY TQD™ tandem quadru-
pole detector mass spectrometer operating as a single analyzer from
Waters. Gradient and detection conditions are shown in Table 1. The
selected m/z values and used operational conditions for the different
compounds are shown in supplemental Table 2. All data were acquired
and processed using MassLynx v4.1 (Waters).
2.6. Analytical features
The stock solutions for 25-HC, 24(S)-HC, 27-HC, 7α-HC, 7β-HC,
4β-HC and 7-ketocholesterol were prepared in methanol at concen-
tration of 1mg mL−1. The working internal standard (IS) solutions
for 25-HC(d6) and 27-HC(d6) were prepared at the same concentra-
tion. All solutions were stored in glass tubes protected from light at
−20°C. Calibration curves were freshly prepared for each batch in
methanol and MilliQ water (9:1, v/v), same solvent as final sample
solvent. The final concentration for the calibration standards of each
compound were 1, 2, 4, 20, 80, 150, 400 and 2000 ng·mL−1. All of
Table 1
Experimental conditions for the quantification of oxysterols in plasma.















Desolvation gas flow 600L/h
Cone gas flow 40L/h
Source temperature 120°C
them were spiked with both IS at 150 ng·mL−1 each one. The lin-
ear dynamic range was determined from the triplicate response of
oxysterol solutions at different concentrations. Limits of detection
(LOD) = 3SD of blank/slope of calibrators and of quantification
(LOQ) = 3.2 LOD were obtained. The determination of intra-day
(n = 5) and inter-day (n = 15) precisions, the recovery and accuracy
of the method were carried out by analyzing plasma spiked with
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by a post-extraction addition procedure, as described by Trufelli et al.
[38]. Basically, four sets of samples were analyzed: a standard solu-
tion with a known concentration (set A), plasma samples spiked with
the same amount of analytes after the sample treatment (set B), plasma
samples spiked with the same amount of analytes before the sample
treatment (set C) and non-spiked plasma samples (set D), to subtract
the endogenous concentration levels. The response of the analytes was
used in the following equations to quantify the matrix effects (Eq. (1)),
the extraction recovery (equation 2) and the process efficiency (Eq.
(3)).
2.7. Statistical analyses
Results are shown as means ± standard deviation of the values.
The data were analyzed using the Prism 5.02 software for Windows
(GraphPad, S. Diego, CA, USA). Comparisons were carried out using
one-way ANOVA and Bonferroni post-hoc test. The statistical signif-
icance was set at p< 0.05.
3. Results
3.1. Initial chromatographic and mass-spectrometric settings
When electrospray ionization is utilized, ammonium adduct forma-
tion of sterols is dependent on the mass spectrometer and, more impor-
tantly, the ionization source used [26,39,40]. To avoid operating prob-
lems involving the mass spectrometer, our equipment required tem-
peratures higher than 50°C. With the source temperature set at 120°C,
the spectra obtained in presence of ammonium salts are shown in sup-
plemental Fig. 1. As can be observed, no ammonium adducts were
formed (expected at m/z 420.3). At this point, fragments correspond-
ing to m/z 385.3 and 367.3, also formed without adding ammonium
acetate, were selected for alternative monitoring. To explore their po-
tential use, several chromatographic conditions were tested (data not
shown). In fact, as depicted in supplemental Fig. 2, the use of gra-
dients containing acetonitrile and ammonium salts decreased the sig-
nals and retarded elution times of 25- and 27-HC when compared
to 0.1% formic acid in methanol-Milli-Q water gradients. The use
of ACQUITY UPLC™ BEH C18 2.1mm × 150mm column in our
chromatographic conditions together with single ion recording allows
rapid and specific determinations of 4β-, 7-, 24-, 25- and 27-HC as
well as 7-KC without derivatization and even the use of 25-HC(d6) as
internal standard (Supplemental Fig. 3 and Supplemental Table 2). In
these chromatographic conditions, 22-HC was also separated (Supple-
mental Fig. 3).
3.2. Preliminary exploration of cholesterol esterases to hydrolyze
hydroxycholesterol esters
As shown in supplemental Fig. 4, plasma incubation with the en-
zyme increased the levels of 25 and 27-HC in each group of rats
compared to plasma without enzyme. The addition of Triton X-100 as
surfactant further increased the concentrations. These results clearly
indicate that the enzymatic approach is a promising method for hy-
droxycholesterol ester cleavage and that the presence of a surfactant
facilitates the action of the enzyme.
Two sources of cholesterol esterase were tested to assess their abil-
ity to cleave hydroxycholesterol esters, one from Pseudomonas and
the other from bovine pancreas. Despite the fact that both enzymes
have been reported to have similar activity regarding cholesterol es-
ters [41], a different behavior was observed with oxysterols. The use
of Pseudomonas enzyme resulted in a stronger signal for both 25- and
27-HC (data not shown).
Representative chromatograms displaying the completeness of
cholesterol ester hydrolysis under different experimental conditions
are reproduced in Fig. 3. They show that increasing the amount of en-
zyme reduced the amount of cholesteryl esters present after a 120min
incubation time. In fact, 1.6U of the Pseudomonas enzyme was able
to hydrolyze all the cholesteryl esters in the sample. A similar result
was obtained using the DeBarber et al. procedure [32]. In contrast, the
alkaline hydrolysis proposed by Mcdonald et al. [26] did not achieve
a complete hydrolysis of cholesterol esters. Overall, these results in-
dicate that Pseudomonas enzyme is perfectly active on its proper sub-
strate and that increasing amounts of enzyme favors complete hydrol-
ysis.
3.3. Comparison of enzymatic and alkaline hydrolysis procedures
Once verified the feasibility of the use of cholesterol esterases to
hydrolyze oxysterol esters, the enzymatic procedure was compared to
conventional alkaline hydrolysis in terms of chromatographic back-
ground. Fig. 4 displays the chromatograms obtained following both
hydrolysis procedures. It is noteworthy that the enzymatic hydrolysis
resulted in a cleaner chromatogram with fewer unknown compounds
than the alkaline hydrolysis. These methods were also compared in
terms of recovery of the internal standard, 25-HC(d6), spiked before
processing. As shown in Supplemental Fig. 5, both alkaline proce-
dures, as proposed by DeBarber et al. [32] and McDonald et al. [26],
resulted in similar recoveries and not significantly different from those
obtained by the enzymatic treatment. The latter recovery was close
to the values obtained for samples without hydrolysis. Thus, the en-
zymatic procedure induces fewer unknown compounds and results in
similar recoveries compared to alkaline methods.
3.4. Analytical features
As shown in Table 2, using the enzymatic method, the LOD were
less than 54pgmL−1 and the LOQ was lower than 171pgmL−1 for
all the assayed oxysterols. Intra-day precision values were less than
5% except for 27-HC and 7-KC. Inter-day precisions were lower than
10% for the different oxysterols. The process efficiencies were around
90% except for 7-HC. Analytical features for alkaline hydrolysis us-
ing the DeBarber et al. method [32] are also included in Table 2. The
LOD was never lower than 325pgmL−1 and the LOQ was lower than
1000pgmL−1. Intra-day precision values were higher than 6%, and in-
ter-day precision was higher than 10% for all assayed oxysterols. The
process efficiencies were lower than 90% except for 25-HC and 7-HC.
These results indicate that the enzymatic hydrolysis provides better
sensitivity and accuracy than the alkaline hydrolysis.
Matrix effects (%) = 100× (B-D)/A (1)
Extraction recovery (%) = 100× (C-D)/(B-D) (2)
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Fig. 3. Influence of analytical methods on chromatograms of plasma cholesterol esters from Cyp7b1-deficient rats. Panel denoted A, standard solution of cholesteryl stearate; B,
plasma without hydrolysis; C, alkaline hydrolysis following method of DeBarber et al.; D, alkaline hydrolysis following method of McDonald et al.; E, plasma treated with 0.4 units
of Pseudomonas enzyme; F, with 0.8 units of the same enzyme; G, with 1.6 units of the same enzyme and H, with 0.8 units of Pseudomonas enzyme plus 0.8 units of pancreas
enzyme. All enzymatic assays were carried out at 37°C for 120min.
3.5. Comparison of enzymatic and alkaline hydrolysis procedures for
oxysterol quantification
The results obtained for 4β-, 7-, 24-, 25- and 27-HC as well as
7-KC from Cyp7b1-deficient rats are shown in Fig. 5. As can be ob-
served, the concentrations of both unesterified 25- and 27-HC were
similar and higher than that of 24-HC. Concentrations of unesterified
4β- and 7-HC were similar and higher than that of 7-KC.
Despite the fact that both alkaline hydrolysis methods gave simi-
lar contents of total 27-HC and 7-HC to the enzymatic, they only dif
fered in the amount of 25-HC detected, the McDonald protocol re-
sulted in lower levels of 25-HC than DeBarber. No 24-HC was de-
tected with the alkaline hydrolysis procedures and the amount of 7-KC
was particularly high and that of 4β-HC remarkably low using the De-
Barber protocol. These results indicate that the amount of 24-HC was
strongly influenced by the alkaline hydrolysis procedure used and that
the profile of other oxysterols is also influenced by alkaline condi-
tions.
Quantification of levels of oxysterols in different species is shown
in Table 3. Cyp7b1-deficient rats showed increased plasma levels
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Fig. 4. Overlapping total ion chromatograms obtained by alkaline and enzymatic hydrolysis methods. The same amount of plasma was used in both procedures. Chromatograms were
acquired using SIR mode.
Table 2
Analytical parameters of the enzymatic and alkaline (deBarber et al.) hydrolysis meth-
ods for total oxysterols.
24-HC 25-HC 27-HC 7-HC 7-KC 4-βHC
Enzymatic
LOD (pg/mL) 7 10 20 53 31 15
LOQ (pg/mL) 22.4 32 64 170 99 48
Intra-day precision (RSD%,
n= 5)
4.92 3.86 6.64 4.77 8.46 4.40
Inter-day precision (RSD%,
n= 15)
8.20 6.35 9.76 7.94 9.28 7.28
Process efficiency (%) 93.50 91.29 90.02 75.82 95.78 89.17
Alkaline
LOD (pg/mL) 325 400 515 718 625 700
LOQ (pg/mL) 1040 1284 1647 2297 2000 2242
Intra-day precision (RSD%,
n= 5)
7.83 6.78 9.02 8.67 11.84 8.26
Inter-day precision (RSD%,
n= 15)
12.56 10.53 11.25 14.16 11.36 13.26
Process efficiency (%) 82.14 90.57 81.40 94.51 78.48 87.17
The determination of intra-day and inter-day precisions, the recovery and accuracy of
the method were carried out by analyzing plasma spiked with 100 ng·mL−1 of different
oxysterols.
24-HC compared to the human plasma. Notable difference was ob-
served regarding 27-HC among rat strains.
4. Discussion
To reduce the unknown compounds generated during alkaline hy-
drolysis, due to the basic environment and high temperatures, and to
shorten the sample processing time, a new procedure has been devel-
oped and optimized that makes use of the ability of cholesterol es-
terases to hydrolyze hydroxycholesterol esters. The proposed method
may be considered as an improvement over previous approaches us-
ing chemical hydrolysis, as it offers the following advantages. First,
it generates fewer unknown compounds since less sterol degrada-
tion was observed. Second, it shows a 90% recovery of the internal
standard. Third, it allows the simultaneous determination of several
oxysterols with acceptable analytical goals. The proposed method
shows an improvement in the LOD and LOQ over conventional pro-
tocols involving alkaline hydrolysis. Indeed, it requires less sample
volume what makes suitable for small animals or pediatrics medi-
cine. Fourth, it requires less sample manipulation by eliminating the
post-alkaline extraction step, its evaporation and subsequent dissolu-
tion. The latter aspects are translated into a reduction of sample pro-
cessing time and, consequently, a higher number of samples processed
per working session. Finally, it avoids the use of alkalis and reduces
the environmental impact as it generates fewer chemical wastes.
Prior to undertaking enzymatic approaches, a considerable effort
was made to adapt previously published analytical conditions to the
mass spectrometer using underivatized samples [26,39,42]. Since the
source temperature should be higher than 50°C to avoid operating
problems involving the mass spectrometer, no ammonium adducts
were observed. Despite this circumstance, the mass spectra of 25-HC
and 27-HC could be used to monitor these metabolites by single
ion recording. Application of previously reported SPE and chromato-
graphic conditions [43] resulted in gradients with higher sensitivities,
suitable for working with 100μL samples. Likewise, using this formic
acid-methanol gradient, Narayanaswamy et al. were able to analyze
200μL samples with no need for derivatization or the use of ammo-
nium adducts [21]. These simplifications may facilitate clinical and
experimental work.
The proposed enzymatic method shows an important reduction of
chromatographic unknown compounds compared to alkaline hydroly-
sis. Widely used to cleave hydroxycholesterol esters, alkaline hydrol-
ysis is the most controversial step and probably the major cause of
their formation because of thermal degradation and the alkaline en-
vironment, which can degrade cholesterol and other products [44].
Regarding thermal degradation, it has been shown that the lower
the hydrolysis temperature, the fewer the degradation products ob-
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Fig. 5. Plasma oxycholesterol concentrations from Cyp7b1-deficient rats according to different methods. Results are mean and standard deviations obtained in plasma samples with-
out hydrolysis (free oxysterol), subjected to alkaline saponification following DeBarber et al. or McDonald et al. and enzymatic hydrolysis using the Pseudomonas enzyme. Free
oxysterols were extracted and determined as detailed in methods. Comparisons were carried out using one-way ANOVA and Bonferroni post-hoc test. a, p< 0.001 vs free oxysterol
method; b, p< 0.001 vs free enzymatic hydrolysis and c p< 0.001 vs DeBarber alkaline hydrolysis.
Table 3















24-HC 40.5 3.8 3.0 2.7 13.4
25-HC 6.8 3.3 3.4 2.3 32.5
27-HC 88.5 54.2 27.9 3.1 4.9
7-HC 36.8 75.1 10.0 12.6 206.2
7-KC 15.6 10.6 6.2 13.4 23.1
4-βHC 30.4 25.1 55.2 52.9 45.6
may influence the background and, thus, the chromatographic base-
line used for calculations, therefore biasing analyte concentrations
or even preventing their calculation. This is particularly relevant for
oxysterols, which are found in very low concentrations. To overcome
these problems, these compounds are derivatized [35,47–50], this ap-
proach gives low LOD and high sensitivity and also less background
for quantitative measurement. However, the latter requires another
step in sample processing, which further increases the time and cost
of analysis. The use of cholesterol esterases to hydrolyze hydroxycho-
lesterol esters, without requiring an alkaline environment or high tem-
peratures, provides an optimal operational setting to overcome those
drawbacks and their consequences. Therefore, a cleaner baseline that
facilitates calculations was obtained.
An additional disadvantage of alkaline hydrolysis is the depen-
dence on the protocol used. As shown in Fig. 3, with pathological sam-
ples, the method proposed by Mcdonald et al. [26] did not achieve
complete hydrolysis of cholesterol esters. This could explain the lower
levels of 25-HC obtained with the Mcdonald method (Fig. 5). How-
ever, it resulted in 27-HC levels similar to those obtained with the en-
zymatic procedure (Fig. 5). The other alkaline protocol proposed [32]
yielded higher amounts of 7-KC. This discrepancy between the two
protocols could be attributed to sample treatment under the specific
conditions of this procedure, lending further support to the hypothesis
of the possible generation of 7-KC during saponification in an alkaline
medium, with high temperatures and high levels of cholesterol in the
sample, as has been proposed [34].
The proposed enzymatic method requires incubation with surfac-
tants to improve activities of the enzymes in the assay. This could
be explained by its role in disassembling the plasma lipoproteins and
facilitating enzyme access to their core, where esterified compounds
are found, or blocking other hydroxycholesterol-protein interactions
that might preclude access of cholesterol esterases. The enzymatic
method for the determination of total oxysterols in plasma fulfills ac-
ceptable analytical goals for this kind of samples [51] in terms of lin-
ear range, limits of detection and quantification, repeatability, inter-
mediate precision, overall efficiency and accuracy (Table 2). These
parameters were satisfactory due to the use of the deuterated in-
ternal standard, 25-HC(d6), which compensates for the disturbances
throughout sample treatment and instrumental analysis (especially
during the ionization process) [43,52]. Regarding to 24-HC, 7-HC,
4β-HC and 7-KC, we did not use their deuterated internal standards
as it should be because when we used 25-HC(d6) and 27-HC(d6) as
internal standards consistent results and good recovery were obtained
(Table 2).
A number of features of enzymatic hydrolysis are translated into
the simplification of sample processing, and constitute further advan-
tages over the alkaline methods. For example, the hydrolysis step of
enzymatic processing was carried out directly on the plasma sample.
Thus, an evaporation and dissolution step required in alkaline hydrol-
ysis was eliminated. In addition, we found that incubations for pe-
riods longer than 120min were clearly detrimental, even when they
were carried out at 37°C, a circumstance that defines a time frame
for sample processing. This effect was particularly relevant for the
25-HC determination since, beyond that point, this compound may
be degraded (data not shown). However, under the described condi-
tions, 27-HC was quite stable in the interval from 120 to 240min.
The above experiment also suggests that, because of the need to avoid
possible degradation, 25-HC determination is more demanding than
that of 27-HC. It is interesting to note that Cyp7b1-deficient rats ac-
cumulate 25-HC but not 27-HC, a fact that would point to the for-
mer as the preferential substrate for this enzyme, in agreement with
the data of Cui et al. obtained from the structural characterization
of human CYP7B1 [53]. In patients having mutations in CYP7B1
[25], the plasma levels of 25-HC were increased about 100-fold while
those of 27-HC were only elevated 6–9 times. However, mice lack-
ing CYP7B1 showed a similar increase of both oxysterols [24]. The
ratios of 27-HC to 25-HC obtained by the enzymatic method for hu-
man and mouse samples (Table 3) were similar to those reported by
Quehenberger et al. [54] and Li-Hawkins et al. [24], respectively.
These data indicate that the phenotypic level of oxysterol present in
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wild-type Fisher rat showed a low level of 27-HC compared to Wistar
rats.
In conclusion, the proposed enzymatic method provides cleaner
chromatograms, quantifies lower concentrations of oxysterols without
using derivatization, and is as accurate as the methods currently used.
It also represents a simplification in sample processing by avoiding
high temperatures, alkaline hydrolysis and further purification steps.
Thus, more samples may be processed within a given time period,
without using hazardous alkalis, a circumstance that results in clear
benefits for operators and in reduced costs. Moreover, an increase in
the number of samples processed, make it suitable for large scale clin-
ical samples and for the measurement of oxysterols in tissues. For all
these reasons, the proposed simplification is expected to expand the
determination of these compounds to investigate their role in several
diseases.
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